Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record.

Multidrug resistance (mdr) genes in human cancer

Open access
Nooter, K, Herweijer, H·1991·British Journal of Cancer

Abstract

cancer patients. Using cell lines made resistant to anticancer agents, several types of drug resistance have been characterised, among which are alterations in target proteins (Cabral et al., 1980; Flintoff & Essani, 1980), carrier mediated drug uptake (Redwood & Colvin, 1980; Sirotnak et al., 1981), cellular drug metabolism (Aronow et al., 1984) and cellular repair mechanisms (Bedford & Fox, 1982). A very intriguing development in drug resistance research is the discovery of the phenomenon of multidrug resistance (MDR) (Bradley et al., 1988; van der Bliek & Borst, 1989). In MDR cells, selection for resistance to 'naturally occurring' drugs, e.g. anthracyclines, vinca alkaloids, podophyllotoxins, and colchicine, results in the development of cross-resistance to other members of the MDR drug family (Bech-Hansen et al., 1976; Dan0, 1972; Inaba & Johnson, 1977; Skovsgaard, 1978). The MDR related drugs are structurally dissimilar and have different intracellular targets. What these drugs have in common is that they are lipophilic compounds derived from various natural products. In general, MDR cells are not cross-resistant to alkylating agents (e.g. chlorambucil and cyclophosphamide), antimetabolites (e.g. cytarabine, methotrexate, and 5-fluorouracil), or cisplatin. A striking feature of the classical MDR phenotype is its reduced ability to accumulate drugs, as compared to the parent cell lines. This reduced drug accumulation is most likely the main cause of multidrug resistance (Dan0, 1973; Kessel & Bosmann, 1970; Riehm & Biedler, 1972; Sirotnak et al., 1986, among other references). It is assumed that the reduced drug accumulation is due to activity of an energy dependent unidirectional drug efflux pump with broad substrate specificity. This drug pump is composed of a transmembrane glycoprotein (P-glycoprotein) with a molecular weight of 170 kD (Chen et al., 1986; Gerlach et al., 1986; Gros et al., 1986). It uses energy in the form of ATP to transport drugs through a channel formed by the transmembrane segments (Hamada & Tsuruo, 1988; Horio et al., 1988). Different P-glycoprotein isoforms have been identified, and these are encoded by a family of closely related genes. They are referred to as pgp genes in hamsters and mdr genes in humans and mice (Ng et al., 1989). In humans, two P-glycoprotein isoforms (mdrl and mdr3) with 80% amino acid homology have been identified (Roninson et al., 1986; van der Bliek et al., 1987). By cross-hybridisation of human genomic DNA, Roninson and co-workers isolated two mdr specific genomic clones designated as mdrl and mdr2 (Ronin-

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.1991.152

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 206

Metadata

Authors
Nooter, K., & Herweijer, H.
Venue
British Journal of Cancer
Published
1991-05
Volume
63
Issue
5
Pages
663-669
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2014480866
Cited by
206
References
0
FWCI
9.84
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multidrug resistance (mdr) genes in human cancer. https://app.cochat.ai/papers/10.1038/bjc.1991.152
The paper
Nooter, K., & Herweijer, H. (1991). Multidrug resistance (mdr) genes in human cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.1991.152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.